Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
53
SBMFF Quote, Financials, Valuation and Earnings
Last price:
$0.87
Seasonality move
:
-3.14%
Day range:
$0.87 - $0.87
52-week range:
$0.37 - $1.24
Dividend yield:
1.32%
P/E ratio:
30.49x
P/S ratio:
3.70x
P/B ratio:
4.10x
Volume:
--
Avg. volume:
162
1-year change:
92.09%
Market cap:
$15.6B
Revenue:
$4B
EPS (TTM):
$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.54 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$26M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
$0.87 | -- | $15.6B | 30.49x | $0.01 | 1.32% | 3.70x |
|
HCM
HUTCHMED (China) Ltd.
|
$14.16 | $22.54 | $2.4B | 5.28x | $0.00 | 0% | 4.09x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
$0.81 | -- | $8.9M | 8.18x | $0.00 | 0% | 0.75x |
|
PRE
Prenetics Global Ltd.
|
$13.93 | $26.00 | $234.4M | -- | $0.00 | 0% | 2.71x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$16.00 | -- | $7.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
23.1% | 0.796 | -- | 1.14x |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.509 | -- | 4.41x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global Ltd.
|
1.29% | 4.220 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 21.200 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SBMFF
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
Sino Biopharmaceutical Ltd. vs. Competitors
-
Which has Higher Returns SBMFF or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About SBMFF or HCM?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.54 which suggests that it could grow by 59.21%. Given that HUTCHMED (China) Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is SBMFF or HCM More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.715, which suggesting that the stock is 28.542% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.402%.
-
Which is a Better Dividend Stock SBMFF or HCM?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.32%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or HCM?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while HUTCHMED (China) Ltd.'s PE ratio is 5.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.70x versus 4.09x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.70x 30.49x -- -- HCMHUTCHMED (China) Ltd.4.09x 5.28x -- --
-
Which has Higher Returns SBMFF or HKPD?
Hong Kong Pharma Digital Technology Holdings Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- -
What do Analysts Say About SBMFF or HKPD?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than Hong Kong Pharma Digital Technology Holdings Ltd., analysts believe Sino Biopharmaceutical Ltd. is more attractive than Hong Kong Pharma Digital Technology Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 -
Is SBMFF or HKPD More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.715, which suggesting that the stock is 28.542% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBMFF or HKPD?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.32%. Hong Kong Pharma Digital Technology Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or HKPD?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while Hong Kong Pharma Digital Technology Holdings Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.70x versus 0.75x for Hong Kong Pharma Digital Technology Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.70x 30.49x -- -- HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- --
-
Which has Higher Returns SBMFF or PRE?
Prenetics Global Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of -28.82%. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About SBMFF or PRE?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 122.54%. Given that Prenetics Global Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Prenetics Global Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 PREPrenetics Global Ltd.1 0 0 -
Is SBMFF or PRE More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.715, which suggesting that the stock is 28.542% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBMFF or PRE?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.32%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or PRE?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.70x versus 2.71x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.70x 30.49x -- -- PREPrenetics Global Ltd.2.71x -- $23.6M -$6.8M
-
Which has Higher Returns SBMFF or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBMFFSino Biopharmaceutical Ltd.-- -- $7.2B RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About SBMFF or RGC?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Sino Biopharmaceutical Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBMFFSino Biopharmaceutical Ltd.0 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is SBMFF or RGC More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.715, which suggesting that the stock is 28.542% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBMFF or RGC?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.01 per share corresponding to a yield of 1.32%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 65.96% of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBMFF or RGC?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 30.49x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.70x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBMFFSino Biopharmaceutical Ltd.3.70x 30.49x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 195.13% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 0.37% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 2% over the past day.
